184 related articles for article (PubMed ID: 11122832)
21. Antibody therapy for residual disease in acute myelogenous leukemia.
Jurcic JG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):37-45. PubMed ID: 11255080
[TBL] [Abstract][Full Text] [Related]
22. Targeted alpha-particle immunotherapy for acute myeloid leukemia.
Jurcic JG; Rosenblat TL
Am Soc Clin Oncol Educ Book; 2014; ():e126-31. PubMed ID: 24857092
[TBL] [Abstract][Full Text] [Related]
23. Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation.
Ritz J
Clin Haematol; 1983 Oct; 12(3):813-32. PubMed ID: 6357582
[No Abstract] [Full Text] [Related]
24. [ABO incompatibility in allogeneic bone marrow transplantation].
Quabeck K; Beelen DW; Mahmoud HK; Schaefer UW; Schmidt CG; Henneberg-Quester KB; Luboldt W
Beitr Infusionther Klin Ernahr; 1987; 18():310-5. PubMed ID: 3326589
[No Abstract] [Full Text] [Related]
25. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
Jurcic JG
Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy for hematopoietic cell transplantation.
Jurcic JG
Immunotherapy; 2013 Apr; 5(4):383-94. PubMed ID: 23557421
[TBL] [Abstract][Full Text] [Related]
27. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
Frankel AE; Sievers EL; Scheinberg DA
Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
[TBL] [Abstract][Full Text] [Related]
28. Recent trends in the treatment and prognosis of adult leukemia with characteristics of patients in Japan: transition during the fifteen years from 1971 to 1985.
Suzuki H; Ota K; Ohno R; Masaoka T; Shibata H; Kimura I; Amaki I; Miura Y; Uzuka Y; Kawato M
Jpn J Clin Oncol; 1989 Dec; 19(4):338-47. PubMed ID: 2607637
[TBL] [Abstract][Full Text] [Related]
29. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic marrow transplantation.
Sullivan KM; Storb R
Cancer Invest; 1984; 2(1):27-38. PubMed ID: 6367899
[TBL] [Abstract][Full Text] [Related]
31. [Principles of treatment of children with leukemia].
van der Does-van den Berg A; de Vries JA
Tijdschr Kindergeneeskd; 1982 Dec; 50(6):211-8. PubMed ID: 6762697
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow transplantation for treatment of leukemia in children.
Trigg ME
Pediatr Clin North Am; 1988 Aug; 35(4):933-48. PubMed ID: 3047659
[TBL] [Abstract][Full Text] [Related]
34. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia.
Ritz J; Sallan SE; Bast RC; Lipton JM; Nathan DG; Schlossman SF
Haematol Blood Transfus; 1983; 28():117-23. PubMed ID: 6345287
[No Abstract] [Full Text] [Related]
35. European experience of bone marrow transplantation for leukemia.
Ringdén O; Zwaan F; Hermans J; Gratwohl A
Transplant Proc; 1987 Feb; 19(1 Pt 3):2600-4. PubMed ID: 3547941
[No Abstract] [Full Text] [Related]
36. Antibody-targeted chemotherapy of relapsed AML.
Mineur P; Lejeune C; Hennaux V; Eten C
Br J Haematol; 2003 Apr; 121(1):195-6. PubMed ID: 12670356
[No Abstract] [Full Text] [Related]
37. Autologous stem cell transplantation in acute myelocytic leukemia.
Gorin NC
Blood; 1998 Aug; 92(4):1073-90. PubMed ID: 9694694
[No Abstract] [Full Text] [Related]
38. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates.
Sievers EL
Cancer Chemother Pharmacol; 2000; 46 Suppl():S18-22. PubMed ID: 10950142
[TBL] [Abstract][Full Text] [Related]
39. Biological differences in the three major leukaemias.
Gratwohl A
Lancet; 1988 Aug; 2(8607):403. PubMed ID: 2899815
[No Abstract] [Full Text] [Related]
40. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
